DarioHealth Corp. (DRIO) vs Werewolf Therapeutics, Inc. (HOWL)
A side-by-side comparison of DarioHealth Corp. and Werewolf Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DRIO
DarioHealth Corp.
$6.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
HOWL
Werewolf Therapeutics, Inc.
$0.92HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — DRIO vs HOWL
growth of $100 · dividends reinvested · last 5yDRIO -98.7% (-57.8%/yr)HOWL -94.2% (-43.5%/yr)HOWL compounded faster over this window
DRIO HOWL
DRIO vs HOWL: by the numbers
- •HOWL is the larger company ($45M vs $44M market cap).
- •DRIO is profitable (322.77% net margin) while HOWL runs a net loss (-164.82%).
Metrics side by side
Valuation
| Metric | DRIO | HOWL |
|---|---|---|
| P/E ratio | 8.72 | N/A |
| P/S ratio | 2.10 | 2.13 |
| P/B ratio | 0.80 | 2.74 |
Profitability
| Metric | DRIO | HOWL |
|---|---|---|
| Gross margin | 56.09% | 0.00% |
| Operating margin | -163.94% | 0.00% |
| Net margin | 322.77% | -164.82% |
| ROE | 123.04% | -212.45% |
| ROIC | -78.42% | -156.97% |
Growth (annualized)
| Metric | DRIO | HOWL |
|---|---|---|
| Revenue CAGR (5Y) | 10.10% | N/A |
| Total return CAGR (5Y) | -52.92% | -44.27% |
Frequently asked
- Is DRIO or HOWL more profitable?
- DRIO runs the higher net margin — DRIO at 322.77% versus HOWL at -164.82%.
- How have DRIO and HOWL total returns compared?
- Over the past 5 years, DRIO delivered -52.92% and HOWL delivered -44.27% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
DarioHealth P/E ratioDarioHealth ROEWerewolf Therapeutics ROEDarioHealth operating marginWerewolf Therapeutics operating marginDarioHealth revenue growthWerewolf Therapeutics revenue growthDarioHealth free cash flowWerewolf Therapeutics free cash flow
DarioHealth & Werewolf Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.